Mandara Biopharma launches Phase 2/3 Alzheimer’s agitation trial in Australia

Mandara Biopharma has started a Phase 2/3 clinical trial in Australia for agitation linked to Alzheimer’s disease. The study could advance a new treatment option for a symptom that affects patients, caregivers and long-term care facilities.

Why it matters: - Agitation is one of the most difficult symptoms in Alzheimer’s disease and can raise emotional, physical and financial strain on caregivers and care facilities. - The condition affects an estimated 60% of people with mild cognitive impairment and 76% of patients with Alzheimer’s dementia. - A successful trial could add a new treatment option for a symptom that has a direct impact on quality of life and care costs.

What happened: - Mandara Biopharma launched its Phase 2/3 clinical trial in Australia for agitation associated with Alzheimer’s disease. - The privately held U.S.-based biopharmaceutical company focuses on novel therapies for central nervous system disorders. - CEO David Hurley said the launch of the FDA-approved clinical trial protocol in Australia is an important milestone for the company.

The details: - The trial is designed to study a potential new therapeutic option for Alzheimer’s-related agitation. - Mandara Biopharma said its goal is to bring forward a rigorously studied treatment that could improve outcomes for patients, caregivers and care facilities. - Alithia, an Australian-based contract research organization, is partnering on the study. - Alithia focuses on clinical research and has experience in neurological conditions, including dementia. - Alithia said its team brings an average of 15+ years of industry expertise. - Tina Soulis, founder and director of Alithia, said the organization is pleased to partner with Mandara Biopharma on the study. - Mandara Biopharma’s pipeline includes therapies for Alzheimer’s agitation, traumatic brain injury and PTSD. - The company lists a 2027 scheduled launch for Alzheimer’s agitation, 2029 for traumatic brain injury and 2030 for PTSD. - More information is available on Mandara Biopharma’s website.

Between the lines: - The Australian launch suggests Mandara Biopharma is moving a lead CNS program into a larger clinical-development phase. - A study focused on agitation targets a symptom that often drives institutional burden, so results could matter beyond the Alzheimer’s drug market itself. - The partnership with a local CRO may help support trial execution in Australia and add operational expertise in dementia research.

What's next: - Mandara Biopharma will continue the Phase 2/3 trial and evaluate whether the treatment can help reduce agitation linked to Alzheimer’s disease. - The company’s forward-looking plan points to additional pipeline milestones across Alzheimer’s agitation, traumatic brain injury and PTSD. - Any future progress will depend on trial results and regulatory review.